A Study of the Safety, Tolerability, and Clinical Pharmacology of Subcutaneous Rjv001 in Adult Subjects Undergoing Abdominoplasty
Latest Information Update: 19 Jan 2022
At a glance
- Drugs RJV 001 (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions
- Sponsors Rejuvenon
- 14 Jan 2022 Status changed from recruiting to completed.
- 20 Apr 2021 Planned initiation date (Estimated date of first participant enrollement) changed from 1 Apr 2021 to 21 Apr 2021.
- 20 Apr 2021 Status changed from not yet recruiting to recruiting.